Home › Therapeutic areas › Immunology › Ulcerative Colitis
Ulcerative Colitis (8 companies)
Companies with an active program in Ulcerative Colitis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABVX | Abivax | Immunology | 1 | Phase 3 | $7.50B | 2 |
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | $241M | 6 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 1 | Phase 3 | $11.2M | 8 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | $197M | 3 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 1 | Approved | $8.62B | 12 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 6 | Phase 2 | $9.86B | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.68B | 28 |
No companies match.